Seres Therapeutics names Richard Kender as interim CEO

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ACCV
3. SPY
4. QQQ
5. AZN
6. FICO
7. SMMT
8. GMAB
9. SAIQ
10. IVBIY

Go back to Seres Therapeutics names Richard Kender as interim CEO

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

March 2, 2026 4:05 PM EST

Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience

Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155 study in immune checkpointrelated enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, expected in Q2 2026

SER-155 is Phase 2 ready for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) to treat hematologic malignancies (cancers of the blood, bone marrow, and lymph nodes); efforts to secure funding for... More